Mon, July 8, 2024

Ashwani Verma Maintained (UTHR) at Strong Buy with Increased Target to $370 on, Jul 8th, 2024

Ashwani Verma of UBS, Maintained "United Therapeutics Corporation" (UTHR) at Strong Buy with Increased Target from $300 to $370 on, Jul 8th, 2024.

Ashwani has made no other calls on UTHR in the last 4 months.



There are 5 other peers that have a rating on UTHR. Out of the 5 peers that are also analyzing UTHR, 1 agrees with Ashwani's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Chris Shibutani of "Goldman Sachs" Maintained at Hold with Increased Target to $240 on, Friday, May 3rd, 2024


These are the ratings of the 4 analyists that currently disagree with Ashwani


  • Tiago Fauth of "Wells Fargo" Maintained at Buy with Increased Target to $350 on, Wednesday, June 12th, 2024
  • Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $300 on, Tuesday, May 21st, 2024
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $400 on, Thursday, May 2nd, 2024
  • Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $300 on, Thursday, May 2nd, 2024